Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (411-420 of 428) with videos related to

Pageof 43
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Cancer Discovery|October 1, 2025
Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal ExpansionDivij Verma, Rachel Zeig-Owens, David G Goldfarb, et al.
Nature Medicine|March 8, 2022
High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disasterSakshi Jasra, Orsi Giricz, Rachel Zeig-Owens, et al.
Cancer Research|June 3, 2026
Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple MyelomaRafael R Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
Research Square|May 5, 2025
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple MyelomaRafael Renatino Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
The New England Journal of Medicine|September 28, 2022
GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Sean M Devlin, Jonathan Landa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2022
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based DietsUrvi A Shah, Kylee H Maclachlan, Andriy Derkach, et al.
JAMA Oncology|April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical TrialOla Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
Blood Cancer Journal|May 18, 2021
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategiesSæmundur Rögnvaldsson, Thorvardur Jon Love, Sigrun Thorsteinsdottir, et al.
Pageof 43

Showing results (411-420 of 428) with videos related to

Sort By:
Pageof 43
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Cancer Discovery|October 1, 2025
Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal ExpansionDivij Verma, Rachel Zeig-Owens, David G Goldfarb, et al.
Nature Medicine|March 8, 2022
High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disasterSakshi Jasra, Orsi Giricz, Rachel Zeig-Owens, et al.
Cancer Research|June 3, 2026
Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple MyelomaRafael R Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
Research Square|May 5, 2025
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple MyelomaRafael Renatino Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
The New England Journal of Medicine|September 28, 2022
GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Sean M Devlin, Jonathan Landa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2022
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based DietsUrvi A Shah, Kylee H Maclachlan, Andriy Derkach, et al.
JAMA Oncology|April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical TrialOla Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
Blood Cancer Journal|May 18, 2021
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategiesSæmundur Rögnvaldsson, Thorvardur Jon Love, Sigrun Thorsteinsdottir, et al.
Pageof 43